Roche’s giredestrant breast cancer treatment approved in the US
By the AFREEQUE newsroom, based on L’essentiel, Business News and Le Quotidien d'Oran
Taxiarchos228 · FALSwiss pharmaceutical giant Roche has obtained its first approval from the US Food and Drug Administration (FDA) for its giredestrant treatment, which will be marketed under the name Wilserdly. It targets adults with advanced disease carrying ESR1 mutations, while a decision on earlier-stage forms is expected by 30 November, according to the company.
Swiss pharmaceutical giant Roche has obtained approval from the Food and Drug Administration, the US medicines agency, for giredestrant, which will be marketed under the name Wilserdly. The treatment, combined with everolimus, targets adults with advanced or metastatic breast cancer carrying ESR1 mutations and resistant to hormone therapy, according to the company in a statement.
Taken orally, the medicine allows patients to continue their treatment at home. For Levi Garraway, Roche’s chief medical officer and head of product development, it can « significantly delay disease progression ».
Roche says an application covering earlier-stage breast cancer is still under review, with a decision expected on 30 November.
Roche points out that, among women, no other cancer causes more deaths than breast cancer. According to the World Health Organization, 2.4 million women worldwide were diagnosed with the disease in 2024, and it caused 694,000 deaths. In Luxembourg, the National Cancer Registry recorded 578 new cases in 2023, and 79 women died from the disease.





